摘要
目的胃癌是我国最常见的恶性肿瘤,早期诊断率很低,多数患者即使能够手术治疗,术后复发率也很高;胃癌是对化疗相对敏感的消化道肿瘤,可是尚无金标准化疗方案,因此,开发新的药物,设计新的方案成为胃癌研究的热点。本研究的目的是观察紫杉醇联合卡培他滨(希罗达)治疗晚期胃癌的临床效果及毒副反应。方法2004年6月～2006年6月,我科用紫杉醇及卡培他滨联合治疗晚期胃癌,资料完整可供分析的共计40例。紫杉醇175mg/m2滴注第1天;卡培他滨2500mg/m2分二次口服第1～14天;每3周为一个周期,至少化疗2个周期。结果40例患者中30例患者肿瘤获得控制,其中CR2例;PR18例;SD10例;PD10例,总有效率为50%(20/40);临床肿瘤控制率为75%(30/40)。毒副反应主要为血液毒性(52.1%)、消化道反应(35.2%)及外周神经毒性(25%),且均仅为Ⅰ/Ⅱ度。结论紫杉醇联合卡培他滨治疗晚期胃癌疗效佳,毒副反应轻,尤其适用于高龄、体质差及其它治疗失败者。
Objective Gastric cancer is the most frequent malignant tumor in China and its early diagnosis rate is very low; though most patients can take operative treatment, the postoperative recurrence rate is very high; gastric cancer is a kind of gastrointestinal tumor that is relatively sensitive to chemotherapy, but there is still no gold standard chemotherapy regimen, therefore, the development of new drugs and the design of new treatment schemes become the hot spot of gastric cancer research. The purpose of this study is to observe the clinical effect and side reactions on the treatment of advanced carcinoma of stomach with the combination of paclitaxel and capecitabine （xeloda）. Methods From June 2004 to June 2006, a total of 40 cases of patients with late gastric cancer treated with the combination of paclitaxel and capecitabine in our department were analyzed, and the data of these patients were completed. On the first day, the patients were given 175mg/ m^2 of paclitaxel by instillation; from tlle first day to the 14th day, the patients were given 1250mg/m^2 of capecitabine by mouth twice a day; the patients received chemotherapy for at least two cycles and each cycle was composed of three weeks of chemotherapy. Results In 40 cases of patients, the tumor of 30 patients was controlled, among them, there were 2 cases of CR, 18 cases of PR, 10 cases of SD and 10 cases of PD; the total effective rate was 50% （20/40） and tile clinical tumor control rate was 75%（30/40）. The major side reactions were hematotoxicity （52.1%）, gastrointestinal reactions （35.2%） and peripheral neurotoxicity （25%）, and the degree of these side reactions were only I /Ⅱ level. Conclusion The curative effect of the combination of paclitaxel and capecitabine was good and its side reactions were slight, which was especially suitable for the eld, weak patients and other treatment failure patients.
出处
《罕少疾病杂志》
2009年第2期24-26,共3页
Journal of Rare and Uncommon Diseases
关键词
胃癌
紫杉醇
卡培他滨
化疗
gastric cancer
paclitaxel
capecitabine
chemotherapy
